PEDIATRICS Vol. 97 No. 6 June 1996, pp. 971-975
This Article
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gerber, M. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gerber, M. A.

Antibiotic Resistance: Relationship to Persistence of Group A Streptococci in the Upper Respiratory Tract

Michael A. Gerber MD1

1 Department of Pediatrics, Connecticut Children's Medical Center, Hartford

Despite the use of penicillin for more than 40 years in treating GABHS infections, there has been no significant change in the in vitro susceptibility of GABHS to penicillin. Reported failures to eradicate GABHS from the upper respiratory tracts of patients with pharyngitis and the apparent resurgence of serious Group A streptococcal infections and their sequelae probably are not related to the emergence of penicillin resistance. Although erythromycin resistance in GABHS had been a major problem in Japan and continues to be a major problem in Finland, it has not been a problem in this country. The susceptibility of GABHS to the newer macrolide antibiotics appears to be similar to that of erythromycin. Comprehensive, community-wide programs to continuously monitor for erythromycin resistance in GABHS would be difficult to justify. However, because little is known about how erythromycin resistance in GABHS is acquired or spread, it would be reasonable to periodically monitor isolates of GABHS for erythromycin resistance. A substantial proportion of GABHS are currently resistant to tetracyclines and these agents are inappropriate for treating GABHS infections. Although little recent information is available about the susceptibility of GABHS to sulfonamides, these agents have been shown to be ineffective in eradicating GABHS from the upper respiratory tract regardless of the in vitro sensitivities. GABHS have not been shown to be resistant to any of the commonly used oral cephalosporins; however, there is a great deal of variability among these agents in their activity against GABHS. Clindamycin resistance in GABHS has remained unusual. This agent is an alternative for treating GABHS infections due to macrolide-resistant strains in patients who cannot be treated with beta-lactam antibiotics.

There is no reason, based on the in vitro susceptibilities of GABHS, to change the current recommendations for treating GABHS infections with penicillin and for using erythromycin for patients who are allergic to penicillin.




This article has been cited by other articles:


Home page
 Clin. Microbiol. Rev.Home page
M. A. Gerber and S. T. Shulman
Rapid Diagnosis of Pharyngitis Caused by Group A Streptococci
Clin. Microbiol. Rev., July 1, 2004; 17(3): 571 - 580.
[Abstract] [Full Text] [PDF]

Home page
 J Med MicrobiolHome page
M. C. Nunes De Melo, A. M. S. Figueiredo, and B. T. Ferreira-Carvalho
Antimicrobial susceptibility patterns and genomic diversity in strains of Streptococcus pyogenes isolated in 1978-1997 in different Brazilian cities
J. Med. Microbiol., March 1, 2003; 52(3): 251 - 258.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
E. Bingen, F. Fitoussi, C. Doit, R. Cohen, A. Tanna, R. George, C. Loukil, N. Brahimi, I. Le Thomas, and D. Deforche
Resistance to Macrolides in Streptococcus pyogenes in France in Pediatric Patients
Antimicrob. Agents Chemother., June 1, 2000; 44(6): 1453 - 1457.
[Abstract] [Full Text]

Home page
 J Antimicrob ChemotherHome page
P. Descheemaeker, S. Chapelle, C. Lammens, M. Hauchecorne, M. Wijdooghe, P. Vandamme, M. Ieven, and H. Goossens
Macrolide resistance and erythromycin resistance determinants among Belgian Streptococcus pyogenes and Streptococcus pneumoniae isolates
J. Antimicrob. Chemother., February 1, 2000; 45(2): 167 - 173.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
D. Cue, S. O. Southern, P. J. Southern, J. Prabhakar, W. Lorelli, J. M. Smallheer, S. A. Mousa, and P. P. Cleary
A nonpeptide integrin antagonist can inhibit epithelial cell ingestion of Streptococcus pyogenes by blocking formation of integrin alpha 5 beta 1-fibronectin-M1 protein complexes
PNAS, March 14, 2000; 97(6): 2858 - 2863.
[Abstract] [Full Text] [PDF]